Oncolytics Biotech, Inc.: An Intro To These Next Few Crucial Weeks
By Michelle Gilson : Oncolytics Biotech, Inc. ( ONCY ) Product: Reolysin and 360 patents worldwide (including methods for oncolytic viral administration) Stock Price: $3.87 Net loss for 2012 expected to be $36 million Oncolytics Biotech, Inc., is a development stage company that is in the process ...
Read the rest of this article on Long Investing Ideas from Seeking Alpha
Related Videos
-
No Sign of Slowdown in Biotech M&AHigh levels of merger and acquisition activity will be the big theme of year for biotech , says Morningstar's Lauren Migliore.
-
Top Biotech Acquisition Candidates2011 was a relatively light year for biotech M&A, but it looks like activity is picking up in 2012.
-
Our Top Five Biotech Takeout PicksHealth-care analyst Lauren Migliore looks at what makes a biotech firm a likely takeout candidate and reveals our top five biotech M&A picks for 2010.